Buyer's Guide

Country:
Zipcode:
Operation:
Search for:
Companies Products Countries ZIP Code (Germany) New Companies
0-9   A   B   C   D   E   F   G   H   I   J   K   L   M   N   O   P   Q   R   S   T   U   V   W   X   Y   Z

Contact | Print version | PDF version | Recommend company

Ablynx nv

Technologiepark 4
9052 Ghent/Zwijnaarde
Belgium

Phone:  +3292620000
Fax:  +3292620001

Contact / Request Information

Portrait
Founded in 2001 in Ghent, Belgium, Ablynx is a biopharmaceutical company focused on the discovery and development of Nanobodies®, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious and life-threatening human diseases. The Company currently has over 200 employees. Ablynx completed a successful IPO on Euronext Brussels [ABLX] on 7 November 2007.

Ablynx is developing a portfolio of Nanobody®-based therapeutic programmes in a number of major disease areas, including inflammation, thrombosis, oncology and Alzheimer’s disease. Nanobodies® have been generated against more than 100 different disease targets. Efficacy data has been obtained in over 25 in vivo models for Nanobodies® against a range of different targets.

Industrial Sectors

  • Medicine/Pharmacy
  • Biotechnology

     
    Additional information
    MyBionity.COM
    Newsletter Subscription
    Your e-mail:
    Top  
    © 2001-2010 Chemie.DE Information Service GmbH
    a Life Science Network Division

     www.Chemie.DE   www.Bionity.COM   www.ChemEurope.COM   www.ChemieKarriere.NET   www.BioKarriere.NET